Kathleen's labs had been normal for three years. She was on medication. She was still disappearing.

This final episode of the thyroid series follows Kathleen through the six months after her extended labs changed everything — and makes a direct case for what Southern Oregon's healthcare infrastructure needs to build so that her story becomes the rule, not a lucky accident.

What produced Kathleen's recovery wasn't a system. It was a series of accidents in her favor: the right book, a physician willing to listen, a phone call that took ten minutes and was worth three years. For every patient who gets those accidents, dozens don't.

Here's what the episode covers:

• Why Kathleen was already on combination therapy and still not getting better — and what the pharmacokinetics of oral T3 reveal about how delivery method matters as much as what you're taking
• The honest evidence on levothyroxine monotherapy: why it works for 80 to 85 percent of patients, and what a mortality dataset of over a million people shows about the meaningful minority it doesn't serve
• The 30 percent all-cause mortality reduction seen in patients on combination T4 and T3 therapy — and why that signal hasn't produced the clinical response it would in any other area of medicine
• Why the liver of a patient on levothyroxine with normal TSH may still be relatively hypothyroid — and what that explains about why statins are the most commonly co-prescribed drug alongside thyroid medication
• Desiccated thyroid extract versus synthetic combination therapy: what the blinded crossover trials actually show, what the legitimate concerns are, and where the ideology on both sides parts ways with the evidence
• What compounded controlled-release T3 claims versus what the only published pharmacokinetic study of those products actually found
• The functional medicine interventions with genuine evidence behind them — and the ones that go well beyond it
• What Kathleen's six-month lab results looked like: free T3, reverse T3 ratio, LDL cholesterol, anti-TPO antibodies — and what changed in her life when the numbers finally moved
• Five specific infrastructure changes Southern Oregon could build now: a shared diagnostic protocol, care coordination pathways between conventional and functional providers, insurance advocacy for comprehensive testing, regional CME, and a prospective outcomes registry

The uncomfortable truth: Good medicine happens when the patient's lived experience is treated as data and the physician's training is a starting point for inquiry, not a closed file. For Kathleen, that combination arrived three years late. The science, the practitioners, and the patients are already here. What's missing is the connective tissue that turns motivated individuals into a system that reliably serves everyone who needs it.

This episode is for you if:

• You've completed the series and want to understand what treatment options the evidence actually supports
• You're a Southern Oregon provider looking for a roadmap grounded in peer-reviewed research
• You believe the parallel silo between conventional and functional medicine is costing patients — and you want to see what closing it looks like in practice

Subscribe to the newsletter at reimagine-healthcare.org for updates on thyroid care in Southern Oregon and new episodes.